New hope for IVF patients: drug may prevent dangerous ovarian overreaction

NCT ID NCT07043322

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two methods to prevent ovarian hyperstimulation syndrome (OHSS), a serious side effect of fertility treatments. About 150 women at high risk for OHSS will receive either cabergoline or a standard 'coasting' procedure. The goal is to see which approach better reduces the occurrence and severity of OHSS.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GYNECOLOGIC DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

female reproductive system disorder ovarian hyperstimulation syndrome prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Mostafa Bahaa

    RECRUITING

    Damietta, New Damietta, 34518, Egypt

    Contact Phone: •••-•••-•••• Email: •••••@•••••